Beschreibung
Anastrozole 1 mg
Brand: Magnus Pharmaceuticals
Content: 30 tablets | 1 mg per tablet
Price: €35
Manufactured in: Europe
🧪 Product Overview
Anastrozole 1 mg is a third-generation non-steroidal aromatase inhibitor (AI) designed to suppress peripheral estrogen synthesis via competitive inhibition of the CYP19 enzyme. Widely used in endocrine and oncology research, it allows for precise estrogen-reduction modeling, testosterone-to-estradiol (T:E) modulation, and post-cycle therapy simulations.
Its long half-life (~46–50 hours) supports once-daily dosing, and the film-coated tablets offer logistical advantages over injectables in hormone-regulation studies. With high selectivity and oral bioavailability, anastrozole is a key tool in studies of male hypogonadism, fertility, and body recomposition protocols.
✅ Key Research Highlights
Selective aromatase blockade:
Inhibits CYP19 to suppress peripheral estrogen by ≥80% in vivo [DrugBank, NCBI]
Extended half-life:
Elimination t½ ≈ 46–50 hours supports consistent once-daily sampling [PubChem, Wikipedia]
T:E ratio modulation:
1 mg/day improved testosterone-to-estradiol ratios and semen metrics in male trials [PMC]
Body recomposition support:
Reduced systemic estrogen helps prevent gynecomastia and sustain lean-mass retention [Verywell Health]
Room-temperature stability:
Film-coated tablets store safely ≤25 °C — no cold-chain required [Mayo Clinic]
🧬 Suggested Laboratory Applications
-
Aromatase inhibition and estrogen-suppression studies
-
Post-cycle therapy and hormonal recovery research
-
T:E ratio modulation in hypogonadal or fertility trials
-
Anti-estrogen support in anabolic-steroid modeling
-
Oncology research in estrogen-dependent tumors
📊 Technical Specifications
| Field | Data |
|---|---|
| Chemical Name | Anastrozole |
| Chemical Formula | C<sub>17</sub>H<sub>19</sub>N<sub>5</sub> |
| Synonyms | Arimidex, ICI D1033, CP-65787, α,α,α′-Tris(1H-1,2,4-triazol-1-yl-m-tolyloxy)-m-xylene |
| Molecular Weight | 293.37 g/mol |
| CAS Number | 120511-73-1 |
| Half-life | 46–50 hours |
| Detection Window | Medium-to-long (varies with dose and sampling) |
| Documented Benefits | ↓ estrogen >80%, ↑ T:E ratio, ↓ recurrence of ER+ breast cancer |
| Main Risks | Arthralgia, hot-flushes, lipid shifts, bone-density reduction |
| Total Active Compound | 30 mg per carton (1 mg × 30 tablets) |
| Shelf-life | 36 months (manufacturer specification) |
❄️ PubChem-Supported Research Insights
-
Suppresses peripheral estrogen synthesis by over 80%
-
Increases T:E ratio in hypogonadal males and fertility models
-
Demonstrated efficacy in reducing recurrence of estrogen-dependent cancers
-
Supports lean tissue retention and gynecomastia control
-
Extended half-life allows single daily dosing for consistent hormonal regulation
⚠️ Documented Research Side Effects
-
Joint pain, bone mineral density reduction, hot-flushes
-
Altered lipid profiles (↓ HDL, ↑ LDL) in chronic use
-
Cardiovascular strain risk with long-term administration
-
Insomnia and mood shifts in estrogen-sensitive models
🧯 Handling & Compliance
For Research Use Only — Not for human or veterinary use
Store at 15–25 °C, protect from moisture and light
Purchase confirms qualified researcher status
Listed on WADA Prohibited List S4 — any exposure may result in a positive anti-doping test
There are no reviews yet.
